Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients

BACKGROUND: Apatinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been used to treat esophagogastric adenocarcinoma. However, the dosage of apatinib varies greatly in clinical practice, and its safety in esophageal squamous cell carcinoma (ESCC) patients is unclear. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Zhang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798775/
https://www.ncbi.nlm.nih.gov/pubmed/35116396
http://dx.doi.org/10.21037/tcr-20-2492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798775/
https://www.ncbi.nlm.nih.gov/pubmed/35116396
http://dx.doi.org/10.21037/tcr-20-2492

Ejemplares similares